McGuireWoods Consulting announced today it has opened a Tallahassee office with the arrival of veteran lobbyists Sean Stafford, Rhett O’Doski and Ryder Rudd.
Tucker Martin will join the MWCAdvocacy team next week as a senior vice president, assisting clients across a variety of industries nationwide with media relations, strategic communications, and grassroots initiatives.
McGuireWoods Consulting is delighted to announce the return of Missy Neff to its Richmond team as a senior vice president for MWCAdvocacy, handling legislative affairs. As part of the MWCAdvocacy team, she will support clients along with a team of additional communications, grassroots, and digital professionals.
McGuireWoods Consulting today announced that Gena McGroarty was promoted to vice president of MWCAdvocacy effective January 1.
Number of the week: 243. That's the number of amendments that has been submitted for the 2018 Federal Aviation Administration (FAA) reauthorization bill (H.R. 4) that is coming up for a vote this week in the House.
Your weekly North Carolina political news report.
This Week: Committees prepare for markups on opioid legislation…OMB says rescissions package is being prepared (the first since 2000).
The General Assembly was buzzing this week while legislative oversight committees continued to wrap up business for the interim. We saw more legislative reports as well as presentations from key stakeholders on disaster relief, school safety, and new agricultural ventures.
On April 18, the House Ways and Means Committee will hold a closed-door meeting to discuss next steps for tax extenders. All House lawmakers are invited to participate in the extenders roundtable, which will be led by Tax Policy Subcommittee Chairman Vern Buchanan (R-FL).
GA-18-380: This report examines the progress the progress the Veterans Health Administration (VHA) has made improving opioid safety through its Opioid Safety Initiative (OSI).
An overview of the upcoming week in Congress from the McGuireWoods Consulting Tax Policy Update Team.
This month, President Trump announced his plan to lower drug prices. The plan does not call for a major overhaul of drug companies’ pricing practices, but does include some proposals that they oppose. Much of Trump’s plan is in the form of suggested actions, and it will take time for actual detailed proposals to be put forward.